InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | 2026-04-29 | Samuel Olivier | Director | Purchase | 81.8K | $2.75 | $225K | 81.8K | View ↗ | |
| 2026-04-27 | 2026-04-29 | Revel Michel | Director & CSO and Director | Purchase | 54.5K | $2.75 | $150K | 957.5K | View ↗ |
No financial data available for NCEL.
Company may not file with SEC or CIK is unresolved.
NLS Pharmaceutics GAAP EPS of -$2.16
Despite NewcelX's Pullback, Insiders Still Gained ₪136k
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference